With more than two decades’ experience in the biopharmaceutical industry, Emergent BioSolutions Inc.’s founder and Executive Chair, Fuad El-Hibri, serves the company he established with a level of experience few can match. Formerly the Rockville, Maryland-based firm’s CEO from 1998 to 2012, he was instrumental in developing the strategic partnerships, product lines, and manufacturing bases that have led the company to be ranked a Top 200 small company by Forbes and
The Washington Post. Fuad El-Hibri has also played a key role in the success of Emergent’s BioThrax, currently the only FDA-approved anthrax vaccine.
Fuad El-Hibri’s extensive career in biopharmaceuticals began after he joined East West Resources Corporation as Chair in 1990, a post he continues to hold today. There, he brought his keen acumen for business development to bear on the 1994 acquisition of the biotechnology company Porton Products LTD, which he re-formed as Speywood Holdings LTD and headed until 1996.
A successful entrepreneur in other industries as well, Mr. El-Hibri has also founded and sold three telecommunications businesses in Russia,
Venezuela, and El Salvador, including Mobile TeleSystems, Digitel, and Digicel. He furthermore possesses experience working in the banking and finance industry. Beginning in 1982, he held senior-level positions at Citibank and Citicorp, as well as Booz Allen Hamilton, for which he helped grow several international banking institutions.
Fuad El-Hibri holds a Bachelor’s in Economics from
Stanford University, and a Master’s in Public and Private Management from Yale School of Management. In a philanthropic capacity, he serves as Chair of the Board of Trustees for The El-Hibri Charitable Foundation, a nonprofit which seeks to foster interfaith dialogue and further Islam’s core values of social justice, peace, and humanitarian aid.